Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ERASNASDAQ:MREONASDAQ:MRSNNASDAQ:XERS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeERASErasca$1.45+4.3%$1.37$1.01▼$3.45$393.77M1.091.75 million shs586,102 shsMREOMereo BioPharma Group$2.72-0.7%$2.48$1.58▼$5.02$435.66M0.471.10 million shs2.01 million shsMRSNMersana Therapeutics$0.34+0.3%$0.36$0.26▼$2.83$42.45M0.832.61 million shs1.11 million shsXERSXeris Biopharma$4.66+0.4%$4.59$2.03▼$6.07$725.62M0.712.01 million shs1.58 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceERASErasca+4.32%+6.23%+18.85%-2.03%-32.87%MREOMereo BioPharma Group-0.73%-2.86%+21.43%+14.77%-27.66%MRSNMersana Therapeutics+0.29%-3.34%-3.04%-16.70%-84.54%XERSXeris Biopharma+0.43%+2.64%-3.52%-18.39%+120.85%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationERASErasca2.0893 of 5 stars3.50.00.00.01.12.51.3MREOMereo BioPharma Group1.2361 of 5 stars3.61.00.00.00.01.70.0MRSNMersana Therapeutics3.8918 of 5 stars3.54.00.04.10.02.50.0XERSXeris Biopharma4.1298 of 5 stars3.42.00.04.22.22.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceERASErasca 3.00Buy$4.57215.27% UpsideMREOMereo BioPharma Group 3.20Buy$7.60179.41% UpsideMRSNMersana Therapeutics 3.00Buy$5.201,422.25% UpsideXERSXeris Biopharma 2.83Moderate Buy$6.2534.12% UpsideCurrent Analyst Ratings BreakdownLatest ERAS, MREO, MRSN, and XERS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2025MRSNMersana TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform5/16/2025MRSNMersana TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $10.005/16/2025MRSNMersana TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.005/15/2025MRSNMersana TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$3.005/14/2025ERASErascaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$3.005/13/2025MREOMereo BioPharma GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.005/9/2025XERSXeris BiopharmaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$6.00 ➝ $7.005/6/2025MRSNMersana TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$4.00 ➝ $3.004/30/2025ERASErascaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.004/9/2025MREOMereo BioPharma GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.003/27/2025MREOMereo BioPharma GroupJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$7.00(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookERASErascaN/AN/AN/AN/A$1.50 per shareN/AMREOMereo BioPharma Group$10M43.25N/AN/A$0.39 per share6.97MRSNMersana Therapeutics$40.50M1.05N/AN/A($0.08) per share-4.27XERSXeris Biopharma$203.07M3.59N/AN/A($0.20) per share-23.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateERASErasca-$161.65M-$0.62N/AN/AN/AN/A-36.56%-31.08%8/11/2025 (Estimated)MREOMereo BioPharma Group-$43.25M-$0.07N/AN/AN/AN/A-69.33%-57.27%8/12/2025 (Estimated)MRSNMersana Therapeutics-$69.19M-$0.59N/AN/AN/A-217.63%-990.16%-48.87%8/12/2025 (Estimated)XERSXeris Biopharma-$54.84M-$0.30N/AN/AN/A-20.25%N/A-12.07%8/6/2025 (Estimated)Latest ERAS, MREO, MRSN, and XERS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025MRSNMersana Therapeutics-$0.21-$0.19+$0.02-$0.19$6.05 million$2.75 million5/13/2025Q1 2025ERASErasca-$0.12-$0.11+$0.01-$0.11N/AN/A5/13/2025Q1 2025MREOMereo BioPharma Group-$0.01-$0.02-$0.01-$0.02$72.50 millionN/A5/8/2025Q1 2025XERSXeris Biopharma-$0.07-$0.06+$0.01-$0.06$57.61 million$57.80 million3/26/2025Q4 2024MREOMereo BioPharma Group$0.02-$0.01-$0.03-$0.01$72.50 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthERASErascaN/AN/AN/AN/AN/AMREOMereo BioPharma GroupN/AN/AN/AN/AN/AMRSNMersana TherapeuticsN/AN/AN/AN/AN/AXERSXeris BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioERASErascaN/A12.3512.35MREOMereo BioPharma GroupN/A8.928.92MRSNMersana Therapeutics13.351.831.83XERSXeris BiopharmaN/A1.721.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipERASErasca67.78%MREOMereo BioPharma Group62.83%MRSNMersana Therapeutics93.92%XERSXeris Biopharma42.75%Insider OwnershipCompanyInsider OwnershipERASErasca14.40%MREOMereo BioPharma Group5.50%MRSNMersana Therapeutics13.00%XERSXeris Biopharma4.56%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableERASErasca120283.29 million242.49 millionOptionableMREOMereo BioPharma Group40159.00 million150.26 millionOptionableMRSNMersana Therapeutics150124.63 million108.43 millionOptionableXERSXeris Biopharma290156.38 million149.25 millionOptionableERAS, MREO, MRSN, and XERS HeadlinesRecent News About These CompaniesXeris Biopharma: Great Numbers, Great Technologies, And Suitable For Long-Term InvestingJune 18, 2025 | seekingalpha.comXeris Biopharma (NASDAQ:XERS) Stock Price Up 8.4% Following Insider Buying ActivityJune 18, 2025 | americanbankingnews.comXeris Biopharma (NASDAQ:XERS) Trading Up 8.4% on Insider Buying ActivityJune 17, 2025 | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Insider Kevin Mcculloch Buys 25,000 SharesJune 17, 2025 | insidertrades.comKevin Mcculloch Purchases 25,000 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) StockJune 16, 2025 | marketbeat.comLeerink Partnrs Estimates Xeris Biopharma FY2025 EarningsJune 9, 2025 | marketbeat.comLeerink Partnrs Cuts Earnings Estimates for Xeris BiopharmaJune 6, 2025 | marketbeat.comXeris Biopharma touts ambitious growth plan, promising hypothyroidism drugJune 4, 2025 | chicagobusiness.comMackenzie Financial Corp Buys 106,153 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)June 4, 2025 | marketbeat.comXeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor DayJune 3, 2025 | finance.yahoo.comXeris Biopharma (NASDAQ:XERS) Shares Down 5.5% - Here's What HappenedJune 3, 2025 | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of "Moderate Buy" from AnalystsJune 3, 2025 | marketbeat.comNuveen Asset Management LLC Acquires 228,380 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)June 1, 2025 | marketbeat.comMillennium Management LLC Raises Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)May 29, 2025 | marketbeat.comBNP Paribas Financial Markets Acquires Shares of 100,012 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)May 28, 2025 | marketbeat.comXeris Announces Details for Analyst & Investor DayMay 20, 2025 | businesswire.comXeris Biopharma Holdings, Inc. (XERS): Among the Unstoppable Growth Stocks to Invest in NowMay 12, 2025 | msn.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2025 Earnings Call TranscriptMay 10, 2025 | insidermonkey.comXeris Biopharma Holdings Inc (XERS) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ...May 9, 2025 | finance.yahoo.comXeris Biopharma Holdings, Inc. (XERS) Q1 2025 Earnings Call TranscriptMay 8, 2025 | seekingalpha.comXeris Biopharma (XERS) Reports Q1 Loss, Tops Revenue EstimatesMay 8, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeERAS, MREO, MRSN, and XERS Company DescriptionsErasca NASDAQ:ERAS$1.45 +0.06 (+4.32%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$1.45 0.00 (0.00%) As of 06/24/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.Mereo BioPharma Group NASDAQ:MREO$2.72 -0.02 (-0.73%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$2.74 +0.02 (+0.92%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.Mersana Therapeutics NASDAQ:MRSN$0.34 +0.00 (+0.29%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$0.35 +0.01 (+3.34%) As of 08:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.Xeris Biopharma NASDAQ:XERS$4.66 +0.02 (+0.43%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$4.64 -0.02 (-0.32%) As of 06/24/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs CrowdStrike Eyes Breakout as Cyber Threats Boost Demand Reddit Stock Ignites: Surge in Call Options Signals Big Bet Insiders Chase Income and Stability in American Tower—Here’s Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
